EcoDrugPlus

Epidermal Growth Factor Receptor

Ensembl ID : ENSHBUG00000010288
Gene Symbol: EGFR
3 Cross references
211 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSHBUG00000000276
Gene Symbol: EGFRA
1 Cross references
211 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSHBUG00000019439
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSHBUG00000006177
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSHBUG00000008515
Gene Symbol: ERBB3
3 Cross references
208 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSHBUG00000013287
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSHBUG00000004534
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSHBUG00000008433
Gene Symbol: ESR1
2 Cross references
215 Possible Orthologues:

Estrogen Receptor Beta

Ensembl ID : ENSHBUG00000012640
Gene Symbol: LOC102296173
3 Cross references
208 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSHBUG00000011554
Gene Symbol: LOC102289622
3 Cross references
198 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSHBUG00000019791
Gene Symbol: ESRRG
3 Cross references
198 Possible Orthologues:

Exportin 1

Ensembl ID : ENSHBUG00000020037
Gene Symbol: XPO1
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).